Overview

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Status:
Completed

Trial end date:
2017-08-10

Target enrollment:

Participant gender:

Summary

Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

BI 409306